The U.S. Food and Drug Administration has proposed an Expedited Investigational New Drug (IND) Pilot Program intended to shorten the time between drug identification and first-in-human (FIH) clinical trials, without weakening participant protections. FDA published the proposal as a Request for Information (RFI) in the Federal Register on June 24, 2026 (Docket No. FDA-2026-N-4699), inviting public comment on the design before any pilot cohort is selected. The program is one of the first concrete initiatives under Operation TrialBlazer, the Department of Health and Human Services’ broader push, announced June 22, 2026, to compress U.S. clinical development timelines and address a documented shift of early-phase trials toward other countries, notably China.
What the pilot actually proposes
The RFI describes a network of “Qualified Research Institutions” (QRIs) — academic medical centers, contract research organizations, and similar entities — that would partner with sponsors ahead of a formal IND submission. Under the proposed model, QRIs would review and issue written recommendations on a sponsor’s nonclinical (pharmacology/toxicology), clinical, and chemistry-manufacturing-controls (CMC) packages on a rolling basis, rather than waiting for a single complete submission. FDA’s stated goal is to let deficiencies surface — and get resolved — earlier, so the agency can issue a “safe to proceed” determination faster once the formal IND is filed, and so parallel IRB review and site activation can start sooner. The RFI also raises the possibility that QRIs could eventually seek a formal FDA certification once the pilot concludes. None of this is settled: the RFI is explicitly a request for input on program design, not a proposed rule, and FDA has not yet announced eligibility criteria, a selection process for QRIs, or a launch date for the pilot itself.
Why now: Operation TrialBlazer
HHS unveiled Operation TrialBlazer on June 22, 2026 as a department-wide effort to accelerate and modernize clinical development in the United States, with the Expedited IND Pilot Program as one of its lead components. The stated aim, echoed in FDA’s own framing of the RFI, is to draw early-phase research back to the U.S. after sponsors increasingly located first-in-human work outside the country — FIH trial startup can currently take substantially longer domestically than in some other markets. FDA has floated a goal of cutting 6–12 months off the time from drug identification to FIH study if the model works as intended, though that figure is a stated program goal, not a guaranteed or binding outcome.
Current status: the comment window is still open
The RFI’s original comment deadline was July 22, 2026. On July 21, 2026, FDA published a Federal Register notice extending that deadline to August 24, 2026, giving sponsors, research institutions, and other stakeholders an additional month to respond before FDA finalizes how — or whether — the pilot proceeds. As of this writing, the docket (FDA-2026-N-4699) remains open for comment on Regulations.gov; FDA has not published a summary of comments received, a list of participating or candidate QRIs, or a pilot start date. Anyone tracking this for institutional planning purposes should treat the program as still in the input-gathering stage, not as an operating pathway sponsors can use yet.
What research administrators and sponsors should watch
For research administration offices, sponsors, and CROs, the near-term action is the comment period itself — this is the stage where questions about QRI eligibility, conflict-of-interest screening, liability, and how a QRI recommendation interacts with FDA’s own review (including the existing pre-IND meeting process and the standard Form FDA 1571 IND submission) can still shape the final design. Institutions that already run substantial early-phase IND-enabling studies programs, or that might consider pursuing QRI status themselves, have the clearest stake in the outcome. The pilot is also worth distinguishing from FDA’s existing expedited programs (Fast Track, Breakthrough Therapy, Accelerated Approval, Priority Review) and from the device-side IND vs. IDE pathway — those are established, codified mechanisms, while the Expedited IND Pilot Program is, for now, a proposal still being shaped by public comment.
